Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045162 · ClinicalTrials.gov registry record · Phase 3
S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer
A Phase 3 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 671
- Enrollment target
NCT00045162 is a Phase 3 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 671 participants.
The verdict
NCT00045162, a Phase 3 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 671 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin combined with irinotecan is more effective than cisplatin combined with etoposide in treating extensive-stage small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of cisplatin combined with either irinotecan or etoposide in treating patients who have extensive-stage small cell lung cancer.
Interventions
- DRUG cisplatin
- DRUG etoposide
- DRUG irinotecan hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 671 participants |
| Start Date | 2002-11 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00045162
The ClinicalTrials.gov registry entry for NCT00045162 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 671 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00045162 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00045162 about?
NCT00045162 is a clinical study titled "S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin combined with irinotecan is more effective than cisplatin combined with etoposide in t...
What is the current status of trial NCT00045162?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 671 participants. The study started on 2002-11. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00045162?
The interventions under investigation include: cisplatin (DRUG), etoposide (DRUG), irinotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00045162?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.